Navigation Links
Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
Date:4/17/2008

n the market for infected diabetic foot ulcers, we view this phase 2 program as a significant step towards treating and potentially preventing this highly serious and widely prevalent complication of diabetes."

About Infected Diabetic Foot Ulcers

According to the Centers for Disease Control and Prevention (CDC), the estimated incidence of diabetes in the US exceeds 1.5 million new cases annually, with an overall prevalence of 20.8 million people, or 7% of the US population. By 2030, the International Diabetes Federation predicts that the Global prevalence of diabetes will almost double from 193 million people (estimated in 2003) to 366 million.

An estimated 15% of patients with diabetes will develop a lower extremity ulcer during the course of their disease. According to a large prospective study, approximately 7% of diabetic patients with foot ulcers will require an amputation. Diabetic foot is the most common cause of nontraumatic lower extremity amputations in the US and Europe, with an average of 82,000 amputations per year in the US costing an estimated $1.6 billion annually. The estimated cost of foot ulcer care in the US ranges from $4,595 per ulcer episode to more than $28,000, for the 2 years post diagnosis. The total annual cost of foot ulcer care in the US has been estimated to be as high as $5 billion.

About Innocoll, Inc.

Innocoll is a privately held, biopharmaceutical company focused on biodegradable surgical implants and topically applied healthcare products. It develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, CollaRx(R) and Liquicoll(R). Innocoll 's lead product, Gentamicin Surgical Implant for the treatment and prevention of surgical site infections, is approved for sale in 49 countries in Europe, Latin America, Middle East, Africa and Asia and is marketed under the following trade names; COLLATAMP(R) G, COLLATAMP(R) EG, SULMYCIN(R)
'/>"/>

SOURCE Innocoll Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
2. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
3. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
4. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
5. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
6. ViroPharma Announces Discontinuation of HCV-796 Development
7. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
8. Free Prostate Cancer Seminar in Lake Ridge, VA: Dr. Charles Snuffy Myers Announces Vitamin D Clinical Trials
9. Phreesia Announces Clinical Initiative to Better Manage Symptoms of Parkinsons Disease
10. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
11. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Calif. , July 24, 2014  IRIDEX Corporation ... will release its second quarter 2014 financial results after ... In conjunction with the release, the Company will ... 5:00 p.m. Eastern Time on Thursday, ... the quarter and other business developments. Interested ...
(Date:7/24/2014)... 2014 Omnicell, Inc. (NASDAQ: ... supply management solutions and analytics software for healthcare ... to discuss the Company,s Second Quarter 2014 financial ... earnings conference call and webcastWhen: , July ... chairman, president and chief executive officer ...
(Date:7/24/2014)... (NYSE MKT: IG), a New Jersey based specialty generic drug ... second quarter ended June 30, 2014. Second Quarter ... in the second quarter of 2014, an increase of 70% ... of $13.3 million for the six months ended June 30, ... 2013 , Total revenues generated from the sale of ...
Breaking Medicine Technology:Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
... Control, WASHINGTON, Jan. 10 To help ... risks during times,of health crisis, DuPont (NYSE: ... products, DuPont(TM) Corian(R) solid surface, has been selected,by ... The product,recently was incorporated into a children,s ward ...
... South Korea, Jan. 10 Celltrion, Inc., a ... and CSL Limited, Australia,s leading biopharmaceutical,company, announced today ... supply of CSL 360, an experimental monoclonal antibody ... Phase I clinical trials for CSL,360 are currently ...
Cached Medicine Technology:DuPont Provides Technology for Washington Hospital Center's Emergency Department 2DuPont Provides Technology for Washington Hospital Center's Emergency Department 3DuPont Provides Technology for Washington Hospital Center's Emergency Department 4Celltrion and CSL Announce Collaboration to Develop and Manufacture Monoclonal Antibody 2
(Date:7/25/2014)... Florida Hospital and MOSI officially announced a transformational partnership that ... and make a difference in the Tampa Bay community. Florida ... provide the support needed to keep the science center moving ... IMAX Dome Theatre from film to a state-of-the-art digital 3D ... in the state of Florida, and it is one of ...
(Date:7/25/2014)... 2014 (HealthDay News) -- The human brain can preserve ... a new study finds. Although dehydration significantly ... have found that the brain compensates by increasing the ... "This research has helped us understand a lot more ... in extreme conditions," study first author Steven Trangmar, a ...
(Date:7/25/2014)... AttorneyOne.com, a recognized authority on law, update the ... on Ibuprofen and Oxcarbazepine Tablets . , The ... and one lot of Oxcarbazepine Tablets, by American Health Packaging ... is used for the treatment of certain types of seizures ... the recall is that Lot #142588, Expiration Date, 01/2016 of ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 A new study ... revealed that 39 percent of all children in the survey ... , The survey looked at 2,505 children during the years of ... four years of age. The final result was that about ... care. Many of these children were from lower-income families and were ...
(Date:7/25/2014)... 25, 2014 A new study of participants ... which are published today in Cancer , found evidence ... 74 who had an abnormal finding on a lung cancer ... of life than did those who were screened and found ... surprise to the researchers. “We expected that participants with an ...
Breaking Medicine News(10 mins):Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 3Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 4Health News:Human Brain Has Coping Mechanism for Dehydration 2Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 3Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 2Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 3Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 4Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 5
... PHILADELPHIA Researchers have made an important step ... autism spectrum disorders. A researcher collaboration, including geneticists ... and The Children,s Hospital of Philadelphia (CHOP), have ... responsible for neurological development, learning and memory, which ...
... As part of Jani-King International, a worldwide leader in ... to fight swine flu influenza A (H1N1) in schools, ... that the number of reported cases in the United ... from trips to Mexico, many schools have shut down ...
... School explains how and why the swine flu virus is threatening humans ... , ... Boston, MA (Vocus) April 28, 2009 -- A new report from ... threatening humans and describes what to do if the infection reaches your ...
... Barnes of Greenway Medical Technologies and Chairman of HIMSS Electronic Health ... Proper Guidelines for Meaningful EHR UseCARROLLTON, Ga., April 28 ... , A total ... will address key aspects of certified electronic health record (EHR) ...
... FRANCISCO, April 28 DIAKADI Body, Personal ... kick off its summer outdoor workout series, the hottest and ... the month of June, individuals of all fitness levels will ... to take on the DIAKADI way of training! The outdoor ...
... provider of healthcare on-demand patient and staff education, healthcare televisions ... Hospital East, in Louisville, KY. , ... ... -- TeleHealth Services , the nation,s leading provider of ...
Cached Medicine News:Health News:Penn Medicine, CHOP researchers demonstrate first common genetic risk factors for autism 2Health News:Jani-King of Cleveland Ready to Fight Swine Flu 2Health News:Harvard Medical School Releases Special Health Report on Swine Flu 2Health News:Health IT Experts Assemble in Washington D.C. to Present Testimony on Definition of Meaningful Use Before National Committee on Vital and Health Statistics (NCVHS) 2Health News:Health IT Experts Assemble in Washington D.C. to Present Testimony on Definition of Meaningful Use Before National Committee on Vital and Health Statistics (NCVHS) 3Health News:Health IT Experts Assemble in Washington D.C. to Present Testimony on Definition of Meaningful Use Before National Committee on Vital and Health Statistics (NCVHS) 4Health News:SF Outdoor Workout Series: Definitely Not Your Typical Boot Camp! 2Health News:SF Outdoor Workout Series: Definitely Not Your Typical Boot Camp! 3Health News:TeleHealth Services Chosen by Baptist Hospital East in Development of New Park Tower 2Health News:TeleHealth Services Chosen by Baptist Hospital East in Development of New Park Tower 3Health News:TeleHealth Services Chosen by Baptist Hospital East in Development of New Park Tower 4
... In vitro diagnostic reagents for ... (CRP) in human serum as well ... means of particle-enhanced Immunonephelometry using the ... increased levels of a number of ...
Peapod Rongeur, 5.5 length 140 mm....
Suitable for children and adults. New mechanical design of the skull pin holder and the clamp base ensures improved rigid skull fixation....
The Skull Pins are inserted into the receptacles of the Skull Clamp and fixate the head during surgery....
Medicine Products: